Abstract 98P
Background
Capecitabine and oxaliplatin combination regimen (CAPOX) is the standard chemotherapeutic care for the treatment of colorectal cancer (CRC). CAPOX treatment is found to be equivalent to FOLFOX and FOLFRI in efficacy and preferred over them due to its easy management and convenience in administration. However, CAPOX treatment was associated with several dose-limiting toxicities and high inter-individual variation in toxicity profile. These toxicities may limit treatment effectiveness as they impose treatment interruption or even discontinuation. Therefore, there is a critical need for identifying the predictive biomarkers for CAPOX related toxicities.
Methods
Patients and methods: In an intent treat analysis, 145 CRC patients were recruited. Patients received a standard treatment schedule of oxaliplatin 130 mg/m2 infusion over 2 hours on day 1 and oral capecitabine 1000mg/m2 in divided doses twice daily for the next 14 days of a 21-day cycle. 5 ml of the venous blood was collected from each patient and genomic DNA was extracted by the phenol-chloroform method. The genotyping analysis of the selected SNP’s was carried out by real-time PCR using TaqMan SNP genotyping assays from applied biosystems.
Results
The major dose-limiting toxicities observed with CAPOX treatment were thrombocytopenia, HFS and PN. DPYD*9 carries were found to be at higher risk for HFS, diarrhoea and thrombocytopenia when compared to patients with wild allele. No significant association was found between DPYD*6, GSTP1 ile105val polymorphisms and CAPOX related toxicities except for thrombocytopenia.
Conclusions
A significant association was observed between DPYD*9A A>G polymorphism and CAPOX induced dose-limiting toxicities like HFS, diarrhoea and thrombocytopenia strengthening its role as a predictive biomarker.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ashok Varma.
Funding
Jawaharlal Institute of Post-Graduate Medical Education and Research (JIPMER).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract